Mangoceuticals (MGRX) Accumulated Expenses (2022 - 2026)

Mangoceuticals has disclosed Accumulated Expenses across 5 years of filings, most recently posting $3297.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3297.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $3297.0 (changed N/A YoY), and the FY2025 annual result was $9421.0, changed N/A from the prior year.
• Accumulated Expenses came in at $3297.0 for Q1 2026 at Mangoceuticals, down from $9421.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9421.0 in Q4 2025 to a low of $2717.0 in Q4 2022.
• The 5-year median for Accumulated Expenses is $5133.5 (2024), against an average of $5556.8.
• Across the five-year window, Accumulated Expenses surged 142.73% in 2023 and sank 36.57% in 2025, its largest moves.
• Mangoceuticals' Accumulated Expenses stood at $2717.0 in 2022, then soared by 142.73% to $6595.0 in 2023, then declined by 15.39% to $5580.0 in 2024, then soared by 68.84% to $9421.0 in 2025, then slumped by 65.0% to $3297.0 in 2026.
• The last three Accumulated Expenses figures came in at $3297.0 (Q1 2026), $9421.0 (Q4 2025), and $4460.0 (Q3 2025), per Business Quant data.